×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Porcine Vaccines Market

ID: MRFR/Pharma/49051-HCR
200 Pages
Rahul Gotadki
October 2025

UK Porcine Vaccines Market Research Report By Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD), Others) and By End-user (Veterinary Hospitals, Hog Production Farm) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Porcine Vaccines Market Infographic
Purchase Options

UK Porcine Vaccines Market Summary

As per Market Research Future analysis, the UK porcine vaccines market Size was estimated at 72.0 USD Million in 2024. The UK porcine vaccines market is projected to grow from 75.9 USD Million in 2025 to 128.52 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.4% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The UK porcine vaccines market is experiencing a transformative shift driven by technological advancements and regulatory influences.

  • Technological advancements in vaccine development are reshaping the UK porcine vaccines market.
  • The regulatory landscape is increasingly influencing vaccine approval processes, impacting market dynamics.
  • The largest segment in the market is driven by rising demand for safe meat products, while the fastest-growing segment focuses on advancements in vaccine technology.
  • Key market drivers include the increasing incidence of swine diseases and consumer preference for sustainable practices.

Market Size & Forecast

2024 Market Size 72.0 (USD Million)
2035 Market Size 128.52 (USD Million)
CAGR (2025 - 2035) 5.41%

Major Players

Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

UK Porcine Vaccines Market Trends

The porcine vaccines market is currently experiencing notable developments, driven by a combination of factors including advancements in vaccine technology and increasing awareness of animal health. The demand for effective vaccines is rising as livestock producers seek to enhance herd immunity and reduce the incidence of diseases that can impact productivity. Regulatory bodies are also playing a crucial role in shaping the landscape, ensuring that vaccines meet stringent safety and efficacy standards. This regulatory environment fosters innovation while maintaining consumer trust in animal products. Moreover, the porcine vaccines market is influenced by changing consumer preferences and the growing emphasis on sustainable farming practices. As consumers become more conscious of food safety and animal welfare, producers are compelled to adopt practices that align with these values. This shift is likely to drive investment in research and development, leading to the introduction of novel vaccines that address emerging health challenges in swine populations. The interplay between regulatory frameworks, consumer expectations, and technological advancements suggests a dynamic future for the porcine vaccines market, with potential for growth and diversification in product offerings.

Technological Advancements in Vaccine Development

Recent innovations in vaccine formulation and delivery methods are transforming the porcine vaccines market. Enhanced efficacy and safety profiles are being achieved through the use of novel adjuvants and delivery systems, which may improve the overall health of swine populations. This trend indicates a shift towards more targeted and effective vaccination strategies.

Regulatory Influence on Vaccine Approval

The regulatory landscape is evolving, with authorities implementing stricter guidelines for vaccine approval and monitoring. This trend emphasizes the importance of safety and efficacy, potentially leading to longer development times but ultimately resulting in higher-quality products in the porcine vaccines market.

Increased Focus on Animal Welfare

There is a growing emphasis on animal welfare within the porcine vaccines market, driven by consumer demand for ethically produced food. This trend encourages producers to adopt vaccination programs that not only enhance productivity but also prioritize the health and well-being of livestock.

UK Porcine Vaccines Market Drivers

Advancements in Vaccine Technology

Innovations in vaccine technology are significantly impacting the porcine vaccines market. The development of novel vaccine formulations, such as subunit and DNA vaccines, appears to enhance efficacy and safety profiles. These advancements may lead to increased adoption rates among farmers, as they seek to protect their herds from diseases like Porcine Reproductive and Respiratory Syndrome (PRRS). The UK market is witnessing a shift towards more effective vaccination strategies, which could potentially increase the overall market size. As of 2025, the market is projected to grow at a CAGR of around 5%, driven by these technological advancements.

Government Initiatives and Support

Government initiatives aimed at improving animal health and welfare are likely to bolster the porcine vaccines market. The UK government has implemented various programs to support livestock health, including funding for research and development of vaccines. Such initiatives may encourage the adoption of vaccination protocols among pig farmers, thereby enhancing herd immunity and reducing disease outbreaks. The financial backing from government sources could lead to a more robust market environment, as stakeholders are incentivized to invest in effective vaccination solutions. This support is crucial for the long-term sustainability of the porcine vaccines market.

Rising Demand for Safe Meat Products

The increasing consumer awareness regarding food safety and quality is driving the porcine vaccines market. In the UK, there is a notable shift towards ensuring that meat products are free from harmful pathogens. This trend is likely to enhance the demand for effective vaccines that can prevent diseases in pigs, thereby ensuring the safety of pork products. The UK pork industry, valued at approximately £1.2 billion, is under pressure to maintain high standards of animal health. Consequently, the porcine vaccines market is expected to grow as producers seek to comply with stringent food safety regulations and consumer expectations.

Increasing Incidence of Swine Diseases

The rising incidence of swine diseases is a critical driver for the porcine vaccines market. Outbreaks of diseases such as African Swine Fever (ASF) and Porcine Epidemic Diarrhea (PED) have raised alarms within the UK pig farming community. These diseases not only threaten animal health but also have significant economic implications, potentially leading to substantial losses for farmers. As a result, there is a heightened urgency to implement vaccination programs to mitigate these risks. The porcine vaccines market is expected to respond positively to this growing concern, as farmers seek effective solutions to protect their livestock.

Consumer Preference for Sustainable Practices

The increasing consumer preference for sustainable farming practices is influencing the porcine vaccines market. UK consumers are becoming more conscious of the environmental impact of livestock farming, leading to a demand for practices that promote animal health and welfare. Vaccination is viewed as a critical component of sustainable farming, as it helps reduce the need for antibiotics and minimizes disease transmission. This shift in consumer attitudes may encourage farmers to invest in vaccination programs, thereby driving growth in the porcine vaccines market. The alignment of vaccination strategies with sustainability goals could enhance market dynamics.

Market Segment Insights

By Type: Inactivated Vaccines (Largest) vs. Live Attenuated Vaccines (Fastest-Growing)

In the UK porcine vaccines market, the distribution among various vaccine types reveals that Inactivated Vaccines hold the largest market share, favored for their efficacy and established use within the industry. Live Attenuated Vaccines, while having a smaller existing market presence, are rapidly gaining traction, particularly among progressive producers looking for innovative solutions to enhance swine health and productivity. Growth trends indicate a notable shift towards the adoption of Live Attenuated Vaccines, driven by advancements in vaccine technology and increasing awareness regarding animal welfare. The demand for effective disease control in livestock is stimulating the development of newer vaccine formulations, allowing these vaccines to become more accessible. Additionally, favorable regulatory frameworks facilitate the entry of novel vaccine types into the market, further accelerating this growth.

Inactivated Vaccines (Dominant) vs. Live Attenuated Vaccines (Emerging)

Inactivated Vaccines are characterized by their long-standing presence in the UK porcine vaccines market, known for their stability and safety. These vaccines are crucial in providing comprehensive immunization against prevalent diseases and have become a standard choice for many farmers. In contrast, Live Attenuated Vaccines represent a rapidly emerging sector, showcasing potential for robust immune responses through live but weakened pathogens. As the market moves toward more efficient disease control, the future of Live Attenuated Vaccines appears promising, propelled by ongoing research and development aimed at maximizing their efficacy and minimizing risks, thus contributing significantly to the overall progression of vaccine utilization in pig farming.

By Disease Indication: PRRS (Largest) vs. PED (Fastest-Growing)

In the UK porcine vaccines market, the distribution of market share among disease indications reveals PRRS as the largest segment. This condition affects reproductive and respiratory health in pigs, and its prevalence significantly drives the demand for effective vaccines. Other notable segments include PED, which while smaller in market share, has been gaining attention due to its increasing incidence in herds across the region. The presence of additional diseases like swine influenza, Aujeszky's disease, and PCVAD also contributes to the overall landscape of the market. Analyzing growth trends, PED emerges as the fastest-growing segment, spurred by rising awareness and proactive measures taken by farmers to mitigate outbreaks. The growth of the PRRS segment continues to be driven by ongoing research and development efforts aimed at improving vaccine efficacy. Furthermore, the overall push towards biosecurity and health management in pig farming fosters a positive environment for vaccine adoption, leading to innovations in formulation and delivery methods.

PRRS (Dominant) vs. PED (Emerging)

Porcine Reproductive & Respiratory Syndrome (PRRS) stands as the dominant segment in the UK porcine vaccines market due to its widespread impact on herd fertility and respiratory health. The presence of PRRS is a major cause for financial losses among swine producers, making effective vaccination essential. As vaccination programs are established and their success rates improve, PRRS vaccines are prioritized by farmers. On the other hand, Porcine Epidemic Diarrhea (PED) is considered an emerging segment, whose severity is characterized by rapid loss of fluids in infected piglets. Farmers are increasingly adopting preventive measures against PED, making it a focal point of intervention strategies. This duality of dominance and emergence highlights the evolving dynamics within the UK porcine vaccines market.

By End-user: Hog Production Farm (Largest) vs. Veterinary Hospitals (Fastest-Growing)

In the UK porcine vaccines market, the market share distribution shows that Hog Production Farms dominate the landscape, holding a significant portion of the overall market. Contributing to this dominance are factors like the increasing scale of pig farming and the heightened focus on herd health management. In contrast, Veterinary Hospitals, while smaller in share, are gaining importance as they cater to the growing demand for specialized and preventive veterinary care in porcine health. The growth trends in this segment are driven by the rising awareness of disease prevention and control in pig populations. As farmers strive for better animal health and production efficiency, the need for effective vaccination strategies intensifies. Furthermore, the Veterinary Hospitals segment is emerging as a vital player due to the increasing collaboration between these facilities and farm producers, which is fostering innovative approaches to vaccination and health management, thus indicating a promising upward growth trajectory.

Hog Production Farm (Dominant) vs. Veterinary Hospitals (Emerging)

Hog Production Farms represent the dominant end-user in the UK porcine vaccines market, characterized by their substantial operational scale and focus on maximizing productivity through advanced health management techniques. These farms invest significantly in health protocols, making vaccines a core component of their husbandry practices. Conversely, Veterinary Hospitals emerge as a growing sector within this market, reflecting a shift towards specialized care and greater demand for preventive health services. The synergy between hog production and veterinary expertise is fostering innovations in vaccine applications, reflecting an evolving landscape focused on enhancing the overall health of swine populations.

Get more detailed insights about UK Porcine Vaccines Market

Key Players and Competitive Insights

The porcine vaccines market in the UK is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on sustainability. Key players such as Zoetis (US), Boehringer Ingelheim (DE), and Merck Animal Health (US) are actively pursuing strategies that emphasize research and development, aiming to introduce novel vaccines that address emerging health challenges in swine populations. This competitive environment is further influenced by the growing demand for high-quality animal health products, driven by consumer preferences for sustainably sourced meat and the need for enhanced biosecurity measures in livestock farming.In terms of business tactics, companies are localizing manufacturing processes and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that hold substantial influence. This dynamic fosters a competitive atmosphere where innovation and operational excellence are paramount, as firms seek to differentiate themselves in a crowded marketplace.

In October Boehringer Ingelheim (DE) announced the launch of a new vaccine targeting Porcine Reproductive and Respiratory Syndrome (PRRS), a significant advancement in the fight against this prevalent disease. This strategic move underscores the company's commitment to addressing critical health issues in swine, potentially enhancing its market position by offering solutions that meet urgent veterinary needs. The introduction of this vaccine is likely to bolster Boehringer Ingelheim's reputation as a leader in porcine health solutions.

In September Merck Animal Health (US) expanded its portfolio by acquiring a biotechnology firm specializing in vaccine development for swine. This acquisition is indicative of Merck's strategy to enhance its research capabilities and accelerate the development of innovative vaccines. By integrating advanced technologies and expertise, Merck aims to strengthen its competitive edge and respond more effectively to the evolving challenges faced by swine producers.

In August Zoetis (US) launched a digital platform designed to provide farmers with real-time data on vaccine efficacy and animal health management. This initiative reflects a broader trend towards digitalization in the animal health sector, where data-driven insights are becoming increasingly vital for decision-making. By leveraging technology, Zoetis positions itself as a forward-thinking player, likely enhancing customer engagement and loyalty through improved service offerings.

As of November the competitive trends in the porcine vaccines market are heavily influenced by digital transformation, sustainability initiatives, and the integration of artificial intelligence in product development. Strategic alliances among key players are shaping the landscape, fostering collaboration that enhances innovation and market responsiveness. Looking ahead, the competitive differentiation is expected to evolve from traditional price-based competition towards a focus on technological advancements, innovative solutions, and reliable supply chains, reflecting the industry's shift towards a more sustainable and efficient future.

Key Companies in the UK Porcine Vaccines Market include

Industry Developments

Recent developments in the UK Porcine Vaccines Market have been notable, particularly with advancements in vaccine formulations and regulatory approvals. Companies like Zoetis and Merck Animal Health have continued to innovate, focusing on improving vaccine efficacy against prevalent diseases in swine populations. Noteworthy is the increasing collaboration among firms, with Valneva announcing partnerships in September 2023 aimed at enhancing their portfolio of vaccines tailored for porcine health.

The market has also seen consolidation activity, with Elanco acquiring a small biotech firm in August 2023 to boost their research capabilities in immunology specifically for swine health, which indicates a trend toward strategic mergers to strengthen market positions.

Furthermore, Vetoquinol has expanded its product line in the UK, reflecting a growing demand for effective porcine vaccines amidst ongoing challenges related to animal health regulations. Over the past two years, the rise in ASF outbreaks in the UK has driven investments and R&D initiatives, positioning the market for further growth as stakeholders aim to enhance biosecurity measures and vaccination strategies. The UK government's support for animal health innovation has also been instrumental in promoting advancements in the porcine healthcare sector.

Future Outlook

UK Porcine Vaccines Market Future Outlook

The Porcine Vaccines Market is projected to grow at a 5.41% CAGR from 2025 to 2035, driven by increasing disease outbreaks, advancements in vaccine technology, and rising demand for pork products.

New opportunities lie in:

  • Development of customized vaccine formulations for specific regional diseases.
  • Expansion of digital platforms for vaccine tracking and management.
  • Investment in research for novel adjuvants to enhance vaccine efficacy.

By 2035, the porcine vaccines market is expected to achieve robust growth and innovation.

Market Segmentation

UK Porcine Vaccines Market Type Outlook

  • Inactivated vaccines
  • Live attenuated vaccines
  • Toxoid vaccines
  • Recombinant vaccines
  • Conjugate vaccines
  • DNA vaccines

UK Porcine Vaccines Market End-user Outlook

  • Veterinary Hospitals
  • Hog Production Farm

UK Porcine Vaccines Market Disease Indication Outlook

  • PED (Porcine Epidemic Diarrhea)
  • PRRS (Porcine Reproductive & Respiratory Syndrome)
  • Swine influenza
  • Aujeszky's disease (AD)
  • Porcine Circovirus Associated Disease (PCVAD)
  • Others

Report Scope

MARKET SIZE 2024 72.0(USD Million)
MARKET SIZE 2025 75.9(USD Million)
MARKET SIZE 2035 128.52(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.41% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR)
Segments Covered Type, Disease Indication, End-user
Key Market Opportunities Advancements in vaccine technology enhance disease prevention in the porcine vaccines market.
Key Market Dynamics Rising demand for innovative porcine vaccines driven by regulatory changes and evolving disease threats in the UK.
Countries Covered UK
Leave a Comment

FAQs

What is the projected market size of the UK Porcine Vaccines Market in 2024?

The UK Porcine Vaccines Market is projected to be valued at 72.0 USD Million in 2024.

What will the UK Porcine Vaccines Market be valued at in 2035?

By 2035, the UK Porcine Vaccines Market is expected to reach a value of 258.0 USD Million.

What is the expected CAGR for the UK Porcine Vaccines Market from 2025 to 2035?

The anticipated CAGR for the UK Porcine Vaccines Market during the forecast period is 12.303%.

Which type of vaccine is expected to have the largest market share in 2035?

In 2035, recombinant vaccines are projected to hold the largest market share valued at 75.0 USD Million.

What are the major players in the UK Porcine Vaccines Market?

Key players in the UK Porcine Vaccines Market include Zoetis, Boehringer Ingelheim, and Elanco among others.

How much is the market for inactivated vaccines projected to grow by 2035?

The market for inactivated vaccines is expected to grow to 54.0 USD Million by 2035.

What is the market value of live attenuated vaccines in 2024?

Live attenuated vaccines are valued at 18.0 USD Million in 2024.

What are the opportunities driving growth in the UK Porcine Vaccines Market?

Opportunities lie in increasing awareness of livestock health and advancements in vaccine technology.

What challenges does the UK Porcine Vaccines Market currently face?

The market faces challenges such as regulatory hurdles and the need for effective vaccine delivery systems.

Is there a significant trend influencing the UK Porcine Vaccines Market?

A significant trend is the shift towards more effective recombinant vaccines and personalized veterinary care.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions